Akili Interactive Labs Archives - Medical Design Sourcing

Layoffs in medtech: These companies recently reduced their workforce

[Image courtesy of Nastuh Abootalebi on Unsplash] The workforce reduction trend has swept the economy recently, and unfortunately, the medtech space is not immune to layoffs.

You’ve probably read about the ongoing layoffs sweeping the tech industry, media and more.

For instance, Yahoo, Disney, Zoom and more all reported workforce reductions as companies across industries grapple with economic pressures. Think inflation, supply chain challenges and more.

Medtech has shown some resilience in the present environment. Some major medical device companies released positive earnings. However, others announced headcount reductions, citing macroeconomic headwinds. Others felt the weight of regulatory issues and restructuring efforts.

Here are a few companies across medtech that enacted layoffs over the past several months.

In 3M’s fourth-quarter earnings report, the company announced that it plans to reduce its global manufacturing workforc…

Akili lays off 46 workers

A child uses the EndeavorRx digital therapeutic. [Image courtesy of Akili]Akili announced that its board of directors approved an operating plan for 2023 that includes a 30% workforce reduction.

The Boston-based digital therapeutic developer’s reduction reaches across different areas and functions. In total, 30% of Akili’s workforce amounts to 46 employees. The company communicated the decision to employees on Jan. 12 and expects to complete the reduction by the end of the first quarter.

Get the full story at our sister site, Drug Delivery Business News.

Akili wins CE mark for digital ADHD treatment

Akili Interactive announced today that it received CE Mark approval for its EndeavorRx video game for children with attention deficit hyperactivity disorder (ADHD).

Boston-based Akili’s prescription treatment is delivered through a video game experience as a way to improve attention function as measured by computer-based testing in children between ages 8 and 12 with primarily inattentive or combined-type ADHD.

Despite garnering CE Mark approval, EndeavorRx is not yet available in Europe. However, the company intends to market the system in European Economic Area member countries while its near-term focus remains on its U.S. launch.

Last week, Akili received FDA clearance through the agency’s de novo pathway as a treatment designed to directly target and activate neural systems through the presentation of sensory stimuli and motor challenges to improve cognitive functioning. The company touts it as the first FDA-cleared prescription treatment deliv…

FDA clears video game Rx for kids with ADHD

Akili Interactive announced that it received FDA clearance for its EndeavorRx video game for children with attention deficit hyperactivity disorder (ADHD).

Boston-based Akili’s prescription treatment is delivered through a video game experience to improve attention function as measured by computer-based testing in children between ages 8 and 12 with primarily inattentive or combined-type ADHD.

EndeavorRx received its review through the FDA’s de novo pathway as a treatment designed to directly target and activate neural systems through the presentation of sensory stimuli and motor challenges to improve cognitive functioning, according to a news release.

Clearance was granted based on data from five clinical studies of more than 600 ADHD-diagnosed children. One prospective, randomized, controlled study published in The Lancet Digital Health Journal revealed that EndeavorRx improved objective measures of attention in children with ADHD.

A…